Standard Heart Drugs Won't Ease Pulmonary
WEDNESDAY, May 18 (HealthDay News) -- Although commonly used to
treat heart disease, aspirin and simvastatin offer no benefit to
patients suffering from pulmonary arterial hypertension, or PAH, a
progressive disease characterized by increased blood pressure in
the arteries of the lungs, according to new research.
In a study funded by the U.S. National Institutes of Health,
researchers divided 65 patients into four groups: one receiving
aspirin; one taking simvastatin; one receiving both drugs; and one
in which patients received a placebo (or dummy pill).
"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population," said Dr. Steven Kawut, study lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine.
After taking the assigned medication for six months, patients
were asked to see how far they could walk in six minutes. The
distance tended to be shorter in the simvastatin group, and no
difference was seen between the aspirin and placebo patients.
Following these early results, the U.S. National Heart, Lung,
and Blood Institute discontinued the study based on a
recommendation from the Data and Safety Monitoring Board.
"The results of this study do not support the routine treatment of PAH with these medications," Kawut said in an American Thoracic Society news release.
The findings are scheduled to be presented Wednesday at the
American Thoracic Society international conference in Denver.
PAH, which is incurable, causes shortness of breath, dizziness
and fatigue, and can lead to heart failure and death.
The researchers concluded that both aspirin and simvastatin may
be prescribed for usual clinical indications in patients with PAH,
but should not be administered specifically to treat PAH.
"The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled [randomized clinical trials] in humans before recommending their use," Kawut said.
Research presented at meetings is considered preliminary until
published in a peer-reviewed journal.
The U.S. National Heart, Lung, and Blood Institute provides more
treatments for pulmonary arterial
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.